Dr. Robert Chen is currently a Professor of Medicine (Neurology) at the University of Toronto, the Catherine Manson Chair in Movement Disorders, Senior Scientist at the Krembil Brain Institute, and Editor-in-Chief of the Canadian Journal of Neurological Sciences. He received his MA and medical degrees (MBBChir) from the University of Cambridge and an M.Sc. from the University of Toronto. He undertook a Neurology residency at the Western University and fellowship at the National Institute of Neurological Disorders and Stroke. His research interests are human motor physiology, brain plasticity and understanding the pathophysiology and the development of new treatments for movement disorders such as Parkinson's disease and dystonia. Dr. Daniel M. Blumberger is the Temerty Chair in Therapeutic Brain Intervention at the Centre for Addiction and Mental Health and a Professor in the Department of Psychiatry at the University of Toronto. He received his MD from the University of Toronto wherehe also completed psychiatry residency and a fellowship in neurostimulation and geriatric psychiatry. He is involved in training and mentoring on the clinical delivery neurostimulation treatments. His research broadly spans the use of neurostimulation therapies for refractory psychiatric disorders with a focus on clinical intervention trials and understanding the neurophysiology of treatment resistant depression across the lifespan. Paul Fitzgerald is Professor of Psychiatry at Monash University and Director of the Epworth Centre for Innovation in Mental Health. He is a qualified psychiatrist, with an MBBS degree, Masters of Psychological Medicine, and research PhD from Monash University. He has conducted an extensive range clinical trials of novel brain stimulation and pharmacological interventions to improve treatment options for patients with depression, schizophrenia, obsessive compulsive disorder, PTSD, autism and Alzheimer's disease along with many experimental studies. He hasestablished multiple clinical TMS services and founded several device and clinical service companies, as well as the first TMS training program in the southern hemisphere.

Dr. Robert Chen is currently a Professor of Medicine (Neurology) at the University of Toronto, the Catherine Manson Chair in Movement Disorders, Senior Scientist at the Krembil Brain Institute, and Editor-in-Chief of the Canadian Journal of Neurological Sciences. He received his MA and medical degrees (MBBChir) from the University of Cambridge and an M.Sc. from the University of Toronto. He undertook a Neurology residency at the Western University and fellowship at the National Institute of Neurological Disorders and Stroke. His research interests are human motor physiology, brain plasticity and understanding the pathophysiology and the development of new treatments for movement disorders such as Parkinson's disease and dystonia. Dr. Daniel M. Blumberger is the Temerty Chair in Therapeutic Brain Intervention at the Centre for Addiction and Mental Health and a Professor in the Department of Psychiatry at the University of Toronto. He received his MD from the University of Toronto wherehe also completed psychiatry residency and a fellowship in neurostimulation and geriatric psychiatry. He is involved in training and mentoring on the clinical delivery neurostimulation treatments. His research broadly spans the use of neurostimulation therapies for refractory psychiatric disorders with a focus on clinical intervention trials and understanding the neurophysiology of treatment resistant depression across the lifespan. Paul Fitzgerald is Professor of Psychiatry at Monash University and Director of the Epworth Centre for Innovation in Mental Health. He is a qualified psychiatrist, with an MBBS degree, Masters of Psychological Medicine, and research PhD from Monash University. He has conducted an extensive range clinical trials of novel brain stimulation and pharmacological interventions to improve treatment options for patients with depression, schizophrenia, obsessive compulsive disorder, PTSD, autism and Alzheimer's disease along with many experimental studies. He hasestablished multiple clinical TMS services and founded several device and clinical service companies, as well as the first TMS training program in the southern hemisphere.

Dr. Robert Chen is currently a Professor of Medicine (Neurology) at the University of Toronto, the Catherine Manson Chair in Movement Disorders, Senior Scientist at the Krembil Brain Institute, and Editor-in-Chief of the Canadian Journal of Neurological Sciences. He received his MA and medical degrees (MBBChir) from the University of Cambridge and an M.Sc. from the University of Toronto. He undertook a Neurology residency at the Western University and fellowship at the National Institute of Neurological Disorders and Stroke. His research interests are human motor physiology, brain plasticity and understanding the pathophysiology and the development of new treatments for movement disorders such as Parkinson's disease and dystonia. Dr. Daniel M. Blumberger is the Temerty Chair in Therapeutic Brain Intervention at the Centre for Addiction and Mental Health and a Professor in the Department of Psychiatry at the University of Toronto. He received his MD from the University of Toronto wherehe also completed psychiatry residency and a fellowship in neurostimulation and geriatric psychiatry. He is involved in training and mentoring on the clinical delivery neurostimulation treatments. His research broadly spans the use of neurostimulation therapies for refractory psychiatric disorders with a focus on clinical intervention trials and understanding the neurophysiology of treatment resistant depression across the lifespan. Paul Fitzgerald is Professor of Psychiatry at Monash University and Director of the Epworth Centre for Innovation in Mental Health. He is a qualified psychiatrist, with an MBBS degree, Masters of Psychological Medicine, and research PhD from Monash University. He has conducted an extensive range clinical trials of novel brain stimulation and pharmacological interventions to improve treatment options for patients with depression, schizophrenia, obsessive compulsive disorder, PTSD, autism and Alzheimer's disease along with many experimental studies. He hasestablished multiple clinical TMS services and founded several device and clinical service companies, as well as the first TMS training program in the southern hemisphere.